Sodium Thiosulfate Inhibits Cis-diamminedichloroplatinum (II) Activity

Overview

Journal Cancer Chemother Pharmacol

Specialty Oncology

Date 1984 Jan 1

PMID 6540631

Citations 15

Authors

J Uozumi

M Ishizawa

Y Iwamoto

T Baba

Affiliations

Soon will be listed here.

Abstract

To elucidate the mechanisms of inactivation of cis-diamminedichloroplatinum(II) (DDP) toxicity by its antidote sodium thiosulfate (STS), we studied the effects of STS on plasma concentrations of platinum (Pt) in vivo, binding of Pt to serum protein in vitro, and uptake of Pt by bacterial cells (E. coli, WP 2 uvrA strain) or cultured mouse tumor cells (FM3A) in vitro. STS did not significantly affect either plasma levels of total Pt or non-protein-bound Pt in vivo, but did inhibit binding of Pt to serum protein and cellular uptake of Pt in vitro. These results suggest that when DDP is given in combination with STS in vivo, the binding to macromolecules and entry of DDP into the cells are prevented due to formation of the Pt-thiosulfate complex in the extracellular fluid.

Citing Articles

The caspase-inhibitor Emricasan efficiently counteracts cisplatin- and neomycin-induced cytotoxicity in cochlear cells.

Nassauer L, Schott J, Harre J, Warnecke A, Morgan M, Galla M J Mol Med (Berl). 2024; 102(9):1163-1174.

PMID: 39110182 PMC: 11358181. DOI: 10.1007/s00109-024-02472-2.

Etchable plasmonic nanoparticle probes to image and quantify cellular internalization.

Braun G, Friman T, Pang H, Pallaoro A, Hurtado de Mendoza T, Willmore A Nat Mater. 2014; 13(9):904-11.

PMID: 24907927 PMC: 4141013. DOI: 10.1038/nmat3982.

Cisplatin nephrotoxicity: molecular mechanisms.

Hanigan M, Devarajan P Cancer Ther. 2008; 1:47-61.

PMID: 18185852 PMC: 2180401.

The effect of sodium thiosulfate on ototoxicity and pharmacokinetics after cisplatin treatment in guinea pigs.

Saito T, Zhang Z, Manabe Y, Ohtsubo T, Saito H Eur Arch Otorhinolaryngol. 1997; 254(6):281-6.

PMID: 9248736 DOI: 10.1007/BF02905989.

WR2721 as a modulator of cisplatin- and carboplatin-induced side effects in comparison with other chemoprotective agents: a molecular approach.

Treskes M, van der Vijgh W Cancer Chemother Pharmacol. 1993; 33(2):93-106.

PMID: 8261581 DOI: 10.1007/BF00685326.

References

Manaka R, Wolf W . Distribution of cis-platin in blood. Chem Biol Interact. 1978; 22(2-3):353-8. DOI: 10.1016/0009-2797(78)90139-4. View

Howell S, Taetle R . Effect of sodium thiosulfate on cis-dichlorodiammineplatinum(II) toxicity and antitumor activity in L1210 leukemia. Cancer Treat Rep. 1980; 64(4-5):611-6. View

Young R, Von Hoff D, Gormley P, Makuch R, Cassidy J, Howser D . cis-Dichlorodiammineplatinum(II) for the treatment of advanced ovarian cancer. Cancer Treat Rep. 1979; 63(9-10):1539-44. View

Yagoda A . Phase II trials with cis-dichlorodiammineplatinum(II) in the treatment of urothelial cancer. Cancer Treat Rep. 1979; 63(9-10):1565-72. View

Patton T, Himmelstein K, Belt R, Bannister S, Sternson L, Repta A . Plasma levels and urinary excretion of filterable platinum species following bolus injection and iv infusion of cis-dichlorodiammineplatinum(II) in man. Cancer Treat Rep. 1978; 62(9):1359-62. View

Gormley P, Bull J, LeRoy A, Cysyk R . Kinetics of cis-dichlorodiammineplatinum. Clin Pharmacol Ther. 1979; 25(3):351-7. DOI: 10.1002/cpt1979253351. View

Green M, Muriel W . Mutagen testing using TRP+ reversion in Escherichia coli. Mutat Res. 1976; 38(1):3-32. DOI: 10.1016/0165-1161(76)90076-5. View

Nakano N . Establishment of cell lines in vitro from a mammary ascites tumor of mouse and biological properties of the established lines in a serum containing medium. Tohoku J Exp Med. 1966; 88(1):69-84. DOI: 10.1620/tjem.88.69. View

Taniguchi S, Baba T . "Two route chemotherapy" using cis-diamminedichloro-platinum(II) and its antidote, sodium thiosulfate, for peritoneally disseminated cancer in rats. Gan. 1982; 73(3):475-9. View

10.

Howell S, Pfeifle C, Wung W, Olshen R . Intraperitoneal cis-diamminedichloroplatinum with systemic thiosulfate protection. Cancer Res. 1983; 43(3):1426-31. View

11.

Einhorn L, Donohue J . Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer. Ann Intern Med. 1977; 87(3):293-8. DOI: 10.7326/0003-4819-87-3-293. View

12.

Sagiyama K, Uozumi J, Aoki K, Baba T . Efficacy of "two-route chemotherapy" using intra-arterial cisplatin and iv sodium thiosulfate, its antidote, in rat bladder tumor. Cancer Treat Rep. 1983; 67(6):567-72. View

13.

Sagiyama K, Uozumi J, Baba T . ["Two route infusion chemotherapy" of cis-diamminedichloro-platinum (II) and its antidote, sodium thiosulfate, for rat bladder tumor (author's transl)]. Nihon Hinyokika Gakkai Zasshi. 1982; 73(3):287-93. DOI: 10.5980/jpnjurol1928.73.3_287. View

14.

Ishizawa M, Taniguchi S, Baba T . Protection by sodium thiosulfate and thiourea against lethal toxicity of cis-diamminedichloroplatinum (II) in bacteria and mice. Jpn J Pharmacol. 1981; 31(6):883-9. DOI: 10.1254/jjp.31.883. View

15.

Uozumi J, Sagiyama K, Aoki K, Iwamoto Y, Baba T . Effectiveness of "two-route chemotherapy" using cisplatin and its antidote, sodium thiosulfate, on lifespan of rats bearing metastatic liver tumors. Cancer Treat Rep. 1983; 67(12):1067-74. View

16.

Dentino M, Luft F, Yum M, Williams S, Einhorn L . Long term effect of cis-diamminedichloride platinum (CDDP) on renal function and structure in man. Cancer. 1978; 41(4):1274-81. DOI: 10.1002/1097-0142(197804)41:4<1274::aid-cncr2820410410>3.0.co;2-f. View

17.

Howell S, Pfeifle C, Wung W, Olshen R, Lucas W, YON J . Intraperitoneal cisplatin with systemic thiosulfate protection. Ann Intern Med. 1982; 97(6):845-51. DOI: 10.7326/0003-4819-97-6-845. View

18.

Madias N, Harrington J . Platinum nephrotoxicity. Am J Med. 1978; 65(2):307-14. DOI: 10.1016/0002-9343(78)90825-2. View

19.

Cole W, Wolf W . Renal toxicity studies of protein-bound platinum(cis). Chem Biol Interact. 1981; 35(3):341-8. DOI: 10.1016/0009-2797(81)90009-0. View

20.

Guarino A, Miller D, Arnold S, Pritchard J, Davis R, Urbanek M . Platinate toxicity: past, present, and prospects. Cancer Treat Rep. 1979; 63(9-10):1475-83. View